A young person with Duchenne muscular dystrophy died following treatment with the recently approved gene therapy ...
The Company is currently analyzing the case and will update the prescribing information for Elevidys to note this development.
A patient has died while taking a closely watched gene therapy for muscular dystrophy. Sarepta Therapeutics announced the ...
Shares of Sarepta Therapeutics SRPT plunged nearly 24% last week after the company reported the death of a patient following ...
Cambridge, Mass.-based Sarepta Therapeutics reported the first known death from its Duchenne muscular dystrophy gene therapy ...
A young man treated with Elevidys died of acute liver failure. The case may give doctors pause before prescribing the ...
After Sarepta reported the death of a patient who had recently taken the gene therapy Elevidys, patient advocacy group Parent ...
The patient, whom Sarepta described as a young man and later told news outlets was 16 years old, suffered acute liver failure ...
Sarepta Therapeutics said that a young man died after receiving Elevidys, its gene therapy for Duchenne muscular dystrophy ...
It’s the first known patient death with the therapy ... scientists about its effectiveness in treating Duchenne muscular dystrophy. It’s the first gene therapy approved in the U.S. for ...